Search
AnaptysBio Inc
ANABAdd to Watchlist
51.060USD
+0.290+0.57%
Market hours 09/24, 10:19（ET）
1.51BMarket Cap
LossP/E TTM
AnaptysBio Inc (ANAB) Stock Price Target & Forecast
Analyst Rating
Based on 11 analysts giving stock ratings to AnaptysBio Inc in the past month.
Buy
4 Strong Buy
7 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
89.875USD+66.68%
ANAB Analyst Recommendation Trends
In the current month, ANAB has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ANAB average Analyst price target in the last month is 89.875.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
4
4
4
5
5
5
5
5
7
7
7
7
7
7
6
6
0
0
1
1
1
1
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11
11
12
13
13
13
13
13
ANAB Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, ANAB EPS is projected to reach 0.003 in FY2026Q2, following reported EPS of -1.843 in FY2026Q1. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q3
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
Forecast
-1.44
0.94
-0.60
0.00
0.60
Actual
0.54
-0.46
-1.84
--
--
Surprise
+137.73%
-149.02%
-205.28%
--
--
FAQs
What is AnaptysBio Inc's expected revenue for the next quarter?
AnaptysBio Inc's expected revenue is 31.11M.
What is AnaptysBio Inc's price target?
Analysts forecast that AnaptysBio Inc's price target is USD 89.88, with the highest forecast at USD 140.00 and the lowest forecast at USD 75.00.
What is the analyst rating for AnaptysBio Inc?
Based on the ratings of AnaptysBio Inc's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.